Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Down 46.5% in February

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 401,483 shares, a drop of 46.5% from the February 12th total of 750,201 shares. Currently, 15.9% of the company’s shares are short sold. Based on an average daily volume of 158,246 shares, the short-interest ratio is presently 2.5 days. Based on an average daily volume of 158,246 shares, the short-interest ratio is presently 2.5 days. Currently, 15.9% of the company’s shares are short sold.

Hedge Funds Weigh In On Aspire Biopharma

Institutional investors have recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. acquired a new stake in shares of Aspire Biopharma during the 3rd quarter worth approximately $28,000. XTX Topco Ltd lifted its position in shares of Aspire Biopharma by 853.2% during the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after acquiring an additional 237,620 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of Aspire Biopharma by 625.8% during the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after acquiring an additional 131,533 shares during the period. 19.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ASBP has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, January 21st. Wall Street Zen upgraded Aspire Biopharma to a “sell” rating in a report on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Aspire Biopharma Stock Performance

Shares of NASDAQ:ASBP traded down $0.13 during midday trading on Thursday, reaching $1.13. The company’s stock had a trading volume of 124,063 shares, compared to its average volume of 1,162,698. Aspire Biopharma has a fifty-two week low of $1.11 and a fifty-two week high of $35.01. The firm has a 50 day moving average price of $2.09 and a two-hundred day moving average price of $8.01. The firm has a market capitalization of $3.03 million, a price-to-earnings ratio of -0.06 and a beta of 0.88.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.